申请人:Eisai R&D Management Co., Ltd.
公开号:US20220017517A1
公开(公告)日:2022-01-20
Provided are compounds represented by the following formulas (I), (II), (III) and (IV) having orexin type 2 receptor-activating activity, or their pharmaceutically acceptable salts.
提供以下化合物的化学式(I)、(II)、(III)和(IV),具有促进俄雷西汀2型受体活性,或其药用可接受的盐。